Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis
Lara J. Herrero(Griffith University), Suresh Mahalingam(Griffith University), Surapee Anantapreecha(Ministry of Public Health), Eric F. Morand(Novartis (Switzerland)), Leilani L. Santos(Royal Women's Hospital), Michelle Nelson(Defence Science and Technology Laboratory), Anon Srikiatkhachorn(University of Rhode Island), Günter Fingerle‐Rowson(University Hospital Cologne), Ran Gu(Monash University), Richard Bucala(Yale University)
Cited by 86
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites
|The Journal of Immunology|2001|957
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726